Clinical trial
Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate…
NCT00040365 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00040365 |
|---|---|
| Title | Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate Cancer |
| Official title | Amifostine as a Rectal Protector During External Beam Radiotherapy for Prostate Cancer: A Phase II Study |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Drug, Radiation |
| Interventions | Amifostine trihydrate, Radiation therapy |
| Enrollment | 30 |
| Start date | Jun 1, 2002 |
| Primary completion | May 1, 2010 |
| Completion | Jun 1, 2011 |
| First posted | Jun 26, 2002 |
| Last update posted | Apr 30, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: